EUVIMEDEUVIMED entdecken
Crossref

Retifanlimab (Zynyz)

CDA-AMC

Canadian Journal of Health Technologies · 19.11.2026 · 6 (11)

DOI: 10.51731/cjht.2026.1571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 19.11.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Retifanlimab (Zynyz), 500 mg/20 mL (25 mg/mL), concentrate for solution, IV infusion. Indication: In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.

Zitieren

APA

CDA-AMC (2026). Retifanlimab (Zynyz). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1571

Vancouver

CDA-AMC. Retifanlimab (Zynyz). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1571

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Retifanlimab (Zynyz)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {11},
  doi = {10.51731/cjht.2026.1571}
}
Kostenlos starten →